Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Single center experience with medical cannabis in Gilles de la Tourette syndrome.

Thaler A, Arad S, Schleider LB, Knaani J, Taichman T, Giladi N, Gurevich T.

Parkinsonism Relat Disord. 2018 Oct 1. pii: S1353-8020(18)30429-2. doi: 10.1016/j.parkreldis.2018.10.004. [Epub ahead of print]

PMID:
30292733
2.

Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes.

Thaler A, Kozlovski T, Gurevich T, Bar-Shira A, Gana-Weisz M, Orr-Urtreger A, Giladi N, Mirelman A.

Mov Disord. 2018 Oct;33(10):1656-1660. doi: 10.1002/mds.27490. Epub 2018 Oct 4.

PMID:
30288804
3.

Dysphagia characteristics in Huntington's disease patients: insights from the Fiberoptic Endoscopic Evaluation of Swallowing and the Swallowing Disturbances Questionnaire.

Manor Y, Oestreicher-Kedem Y, Gad A, Zitser J, Faust-Socher A, Shpunt D, Naor S, Inbar N, Kestenbaum M, Giladi N, Gurevich T.

CNS Spectr. 2018 Sep 10:1-6. doi: 10.1017/S1092852918001037. [Epub ahead of print]

PMID:
30198457
4.

Higher serum cholesterol and decreased Parkinson's disease risk: A statin-free cohort study.

Rozani V, Gurevich T, Giladi N, El-Ad B, Tsamir J, Hemo B, Peretz C.

Mov Disord. 2018 Aug;33(8):1298-1305. doi: 10.1002/mds.27413. Epub 2018 Aug 25.

PMID:
30145829
5.

What predicts falls in Parkinson disease?: Observations from the Parkinson's Foundation registry.

Parashos SA, Bloem BR, Browner NM, Giladi N, Gurevich T, Hausdorff JM, He Y, Lyons KE, Mari Z, Morgan JC, Post B, Schmidt PN, Wielinski CL.

Neurol Clin Pract. 2018 Jun;8(3):214-222. doi: 10.1212/CPJ.0000000000000461. Erratum in: Neurol Clin Pract. 2018 Aug;8(4):278.

PMID:
30105161
6.

Altered reward-related neural responses in non-manifesting carriers of the Parkinson disease related LRRK2 mutation.

Thaler A, Gonen T, Mirelman A, Helmich RC, Gurevich T, Orr-Urtreger A, Bloem BR, Giladi N, Hendler T; LRRK2 Ashkenazi Jewish consortium.

Brain Imaging Behav. 2018 Jul 3. doi: 10.1007/s11682-018-9920-2. [Epub ahead of print]

PMID:
29971685
7.

Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study.

Borm CDJM, Krismer F, Wenning GK, Seppi K, Poewe W, Pellecchia MT, Barone P, Johnsen EL, Østergaard K, Gurevich T, Djaldetti R, Sambati L, Cortelli P, Petrović I, Kostić VS, Brožová H, Růžička E, Marti MJ, Tolosa E, Canesi M, Post B, Nonnekes J, Bloem BR; European MSA Study Group (EMSA-SG).

Parkinsonism Relat Disord. 2018 Jun 8. pii: S1353-8020(18)30274-8. doi: 10.1016/j.parkreldis.2018.06.015. [Epub ahead of print]

PMID:
29910157
8.

Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.

Thaler A, Kliper E, Maidan I, Herman T, Rosenberg-Katz K, Bregman N, Gurevich T, Shiner T, Hausdorff JM, Orr-Urtreger A, Giladi N, Mirelman A.

Brain Topogr. 2018 Nov;31(6):1029-1036. doi: 10.1007/s10548-018-0653-8. Epub 2018 May 30.

PMID:
29846835
9.

Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene.

Thaler A, Bregman N, Gurevich T, Shiner T, Dror Y, Zmira O, Gan-Or Z, Bar-Shira A, Gana-Weisz M, Orr-Urtreger A, Giladi N, Mirelman A.

Parkinsonism Relat Disord. 2018 Oct;55:45-49. doi: 10.1016/j.parkreldis.2018.05.009. Epub 2018 May 17.

PMID:
29784561
10.

Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers.

Mirelman A, Saunders-Pullman R, Alcalay RN, Shustak S, Thaler A, Gurevich T, Raymond D, Mejia-Santana H, Orbe Reilly M, Ozelius L, Clark L, Gana-Weisz M, Bar-Shira A, Orr-Utreger A, Bressman SB, Marder K, Giladi N; AJ LRRK2 Consortium.

Mov Disord. 2018 Jul;33(6):966-973. doi: 10.1002/mds.27342. Epub 2018 Mar 30.

PMID:
29603409
11.

Quantitative species-level ecology of reef fish larvae via metabarcoding.

Kimmerling N, Zuqert O, Amitai G, Gurevich T, Armoza-Zvuloni R, Kolesnikov I, Berenshtein I, Melamed S, Gilad S, Benjamin S, Rivlin A, Ohavia M, Paris CB, Holzman R, Kiflawi M, Sorek R.

Nat Ecol Evol. 2018 Feb;2(2):306-316. doi: 10.1038/s41559-017-0413-2. Epub 2017 Dec 18.

PMID:
29255297
12.

Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience.

Balash Y, Bar-Lev Schleider L, Korczyn AD, Shabtai H, Knaani J, Rosenberg A, Baruch Y, Djaldetti R, Giladi N, Gurevich T.

Clin Neuropharmacol. 2017 Nov/Dec;40(6):268-272. doi: 10.1097/WNF.0000000000000246.

PMID:
29059132
13.

Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.

Zitser J, Peretz C, Ber David A, Shabtai H, Ezra A, Kestenbaum M, Brozgol M, Rosenberg A, Herman T, Balash Y, Gadoth A, Thaler A, Stebbins GT, Goetz CG, Tilley BC, Luo ST, Liu Y, Giladi N, Gurevich T.

Parkinsonism Relat Disord. 2017 Dec;45:7-12. doi: 10.1016/j.parkreldis.2017.09.012. Epub 2017 Sep 24.

14.

Reduced mind wandering in patients with Parkinson's disease.

Geffen T, Thaler A, Gilam G, Ben Simon E, Sarid N, Gurevich T, Giladi N, Shabtai H, Zitser J, Schilman EA, Sharon H.

Parkinsonism Relat Disord. 2017 Nov;44:38-43. doi: 10.1016/j.parkreldis.2017.08.030. Epub 2017 Sep 1.

PMID:
28877857
15.

Two Ethnic Clusters with Huntington Disease in Israel: The Case of Mountain Jews and Karaites.

Zitser J, Thaler A, Inbar N, Gad A, Faust-Socher A, Paleacu D, Anca-Herschkovitch M, Balash Y, Shabtai H, Ash EL, Merkin L, Manor Y, Kestenbaum M, Bar David A, Peretz C, Naiman T, Bar-Shira A, Orr-Urtreger A, Dangoor N, Giladi N, Gurevich T.

Neurodegener Dis. 2017;17(6):281-285. doi: 10.1159/000479375. Epub 2017 Aug 25.

PMID:
28848105
16.

Rituximab as a Second-Line Treatment for Lymphocytic Vasculitis of the Central Nervous System.

Anis S, Sharabi A, Mina Y, Klein A, Cagnano E, Elkayam O, Gurevich T.

Isr Med Assoc J. 2016 Oct;18(10):630-632. No abstract available.

17.

Gently does it: Humans outperform a software classifier in recognizing subtle, nonstereotypical facial expressions.

Yitzhak N, Giladi N, Gurevich T, Messinger DS, Prince EB, Martin K, Aviezer H.

Emotion. 2017 Dec;17(8):1187-1198. doi: 10.1037/emo0000287. Epub 2017 Apr 13.

PMID:
28406679
18.

Statin adherence and the risk of Parkinson's disease: A population-based cohort study.

Rozani V, Giladi N, El-Ad B, Gurevich T, Tsamir J, Hemo B, Peretz C.

PLoS One. 2017 Apr 7;12(4):e0175054. doi: 10.1371/journal.pone.0175054. eCollection 2017.

19.

Subthalamic Neurons Encode Both Single- and Multi-Limb Movements in Parkinson's Disease Patients.

Tankus A, Strauss I, Gurevich T, Mirelman A, Giladi N, Fried I, Hausdorff JM.

Sci Rep. 2017 Feb 13;7:42467. doi: 10.1038/srep42467.

20.

Quality-of-life perception by Parkinson's disease patients and caregivers.

Balash Y, Korczyn AD, Knaani J, Migirov AA, Gurevich T.

Acta Neurol Scand. 2017 Aug;136(2):151-154. doi: 10.1111/ane.12726. Epub 2017 Jan 12.

PMID:
28083960
21.

A "dose" effect of mutations in the GBA gene on Parkinson's disease phenotype.

Thaler A, Gurevich T, Bar Shira A, Gana Weisz M, Ash E, Shiner T, Orr-Urtreger A, Giladi N, Mirelman A.

Parkinsonism Relat Disord. 2017 Mar;36:47-51. doi: 10.1016/j.parkreldis.2016.12.014. Epub 2016 Dec 16.

PMID:
28012950
22.

Sexual Preoccupation Behavior in Parkinson's Disease.

Bronner G, Hassin-Baer S, Gurevich T.

J Parkinsons Dis. 2017;7(1):175-182. doi: 10.3233/JPD-160926. Review.

PMID:
27802244
23.

High Frequency of GBA Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews.

Shiner T, Mirelman A, Gana Weisz M, Bar-Shira A, Ash E, Cialic R, Nevler N, Gurevich T, Bregman N, Orr-Urtreger A, Giladi N.

JAMA Neurol. 2016 Dec 1;73(12):1448-1453. doi: 10.1001/jamaneurol.2016.1593.

PMID:
27723861
24.

Pain in Extrapyramidal Neurodegenerative Diseases.

Yust-Katz S, Hershkovitz R, Gurevich T, Djaldetti R.

Clin J Pain. 2017 Jul;33(7):635-639. doi: 10.1097/AJP.0000000000000437.

PMID:
27623111
25.

Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study.

Peretz C, Segev H, Rozani V, Gurevich T, El-Ad B, Tsamir J, Giladi N.

Clin Neuropharmacol. 2016 Sep-Oct;39(5):227-31. doi: 10.1097/WNF.0000000000000167.

26.

Arm swing as a potential new prodromal marker of Parkinson's disease.

Mirelman A, Bernad-Elazari H, Thaler A, Giladi-Yacobi E, Gurevich T, Gana-Weisz M, Saunders-Pullman R, Raymond D, Doan N, Bressman SB, Marder KS, Alcalay RN, Rao AK, Berg D, Brockmann K, Aasly J, Waro BJ, Tolosa E, Vilas D, Pont-Sunyer C, Orr-Urtreger A, Hausdorff JM, Giladi N.

Mov Disord. 2016 Oct;31(10):1527-1534. doi: 10.1002/mds.26720.

27.

A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers.

Bregman N, Thaler A, Mirelman A, Helmich RC, Gurevich T, Orr-Urtreger A, Marder K, Bressman S, Bloem BR, Giladi N; LRRK2 Ashkenazi Jewish consortium.

Brain Struct Funct. 2017 Apr;222(3):1207-1218. doi: 10.1007/s00429-016-1271-4. Epub 2016 Jul 11.

PMID:
27401793
28.

Cancer incidence among Parkinson's disease patients in a 10-yrs time-window around disease onset: A large-scale cohort study.

Peretz C, Gurel R, Rozani V, Gurevich T, El-Ad B, Tsamir J, Giladi N.

Parkinsonism Relat Disord. 2016 Jul;28:68-72. doi: 10.1016/j.parkreldis.2016.04.028. Epub 2016 Apr 30.

PMID:
27161827
29.

Intact working memory in non-manifesting LRRK2 carriers--an fMRI study.

Thaler A, Helmich RC, Or-Borichev A, van Nuenen BF, Shapira-Lichter I, Gurevich T, Orr-Urtreger A, Marder K, Bressman S, Bloem BR, Giladi N, Hendler T, Mirelman A; LRRK2 Ashkenazi Jewish consortium.

Eur J Neurosci. 2016 Jan;43(1):106-12. doi: 10.1111/ejn.13120. Epub 2015 Dec 18.

PMID:
26536050
30.

New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study.

Pavy-Le Traon A, Piedvache A, Perez-Lloret S, Calandra-Buonaura G, Cochen-De Cock V, Colosimo C, Cortelli P, Debs R, Duerr S, Fanciulli A, Foubert-Samier A, Gerdelat A, Gurevich T, Krismer F, Poewe W, Tison F, Tranchant C, Wenning G, Rascol O, Meissner WG; European MSA Study Group.

J Neurol Neurosurg Psychiatry. 2016 May;87(5):554-61. doi: 10.1136/jnnp-2014-309999. Epub 2015 May 14.

PMID:
25977316
31.

Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene.

Mirelman A, Alcalay RN, Saunders-Pullman R, Yasinovsky K, Thaler A, Gurevich T, Mejia-Santana H, Raymond D, Gana-Weisz M, Bar-Shira A, Ozelius L, Clark L, Orr-Urtreger A, Bressman S, Marder K, Giladi N; LRRK2 AJ consortium.

Mov Disord. 2015 Jun;30(7):981-6. doi: 10.1002/mds.26213. Epub 2015 Mar 21.

32.

Disorders of the oral cavity in Parkinson's disease and parkinsonian syndromes.

Zlotnik Y, Balash Y, Korczyn AD, Giladi N, Gurevich T.

Parkinsons Dis. 2015;2015:379482. doi: 10.1155/2015/379482. Epub 2015 Jan 15. Review.

33.

Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers.

Helmich RC, Thaler A, van Nuenen BF, Gurevich T, Mirelman A, Marder KS, Bressman S, Orr-Urtreger A, Giladi N, Bloem BR, Toni I; LRRK2 Ashkenazi Jewish Consortium.

Neurology. 2015 Jan 27;84(4):399-406. doi: 10.1212/WNL.0000000000001189. Epub 2014 Dec 24.

34.

Head-up tilt testing for detecting orthostatic hypotension: how long do we need to wait?

Gurevich T, Machmid H, Klepikov D, Ezra A, Giladi N, Peretz C.

Neuroepidemiology. 2014;43(3-4):239-43. doi: 10.1159/000368699. Epub 2014 Dec 16.

PMID:
25531748
35.

Levodopa-carbidopa intestinal gel (LCIG) infusion during pregnancy and delivery: first documented case.

Zlotnik Y, Giladi N, Hilel A, Shapira Y, Goldstein S, Gurevich T.

Parkinsonism Relat Disord. 2014 Nov;20(11):1317-8. doi: 10.1016/j.parkreldis.2014.09.018. Epub 2014 Sep 17. No abstract available.

PMID:
25262534
36.

Interdisciplinary teamwork for the treatment of people with Parkinson's disease and their families.

Giladi N, Manor Y, Hilel A, Gurevich T.

Curr Neurol Neurosci Rep. 2014 Nov;14(11):493. doi: 10.1007/s11910-014-0493-1. Review.

PMID:
25245121
37.

Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes.

Vacic V, Ozelius LJ, Clark LN, Bar-Shira A, Gana-Weisz M, Gurevich T, Gusev A, Kedmi M, Kenny EE, Liu X, Mejia-Santana H, Mirelman A, Raymond D, Saunders-Pullman R, Desnick RJ, Atzmon G, Burns ER, Ostrer H, Hakonarson H, Bergman A, Barzilai N, Darvasi A, Peter I, Guha S, Lencz T, Giladi N, Marder K, Pe'er I, Bressman SB, Orr-Urtreger A.

Hum Mol Genet. 2014 Sep 1;23(17):4693-702. doi: 10.1093/hmg/ddu158. Epub 2014 May 19.

38.

Effect of rivastigmine on mobility of patients with higher-level gait disorder: a pilot exploratory study.

Gurevich T, Balash Y, Merims D, Peretz C, Herman T, Hausdorff JM, Giladi N.

Drugs R D. 2014 Jun;14(2):57-62. doi: 10.1007/s40268-014-0038-8.

39.

A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers.

Thaler A, Artzi M, Mirelman A, Jacob Y, Helmich RC, van Nuenen BF, Gurevich T, Orr-Urtreger A, Marder K, Bressman S, Bloem BR, Hendler T, Giladi N, Ben Bashat D; LRRK2 Ashkenazi Jewish Consortium.

Mov Disord. 2014 May;29(6):823-7. doi: 10.1002/mds.25827. Epub 2014 Jan 30.

PMID:
24482120
40.

Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.

Alcalay RN, Mirelman A, Saunders-Pullman R, Tang MX, Mejia Santana H, Raymond D, Roos E, Orbe-Reilly M, Gurevich T, Bar Shira A, Gana Weisz M, Yasinovsky K, Zalis M, Thaler A, Deik A, Barrett MJ, Cabassa J, Groves M, Hunt AL, Lubarr N, San Luciano M, Miravite J, Palmese C, Sachdev R, Sarva H, Severt L, Shanker V, Swan MC, Soto-Valencia J, Johannes B, Ortega R, Fahn S, Cote L, Waters C, Mazzoni P, Ford B, Louis E, Levy O, Rosado L, Ruiz D, Dorovski T, Pauciulo M, Nichols W, Orr-Urtreger A, Ozelius L, Clark L, Giladi N, Bressman S, Marder KS.

Mov Disord. 2013 Dec;28(14):1966-71. doi: 10.1002/mds.25647. Epub 2013 Oct 15.

41.

Parkinson's disease patients first treated at age 75 years or older: a comparative study.

Peretz C, Chillag-Talmor O, Linn S, Gurevich T, El-Ad B, Silverman B, Friedman N, Giladi N.

Parkinsonism Relat Disord. 2014 Jan;20(1):69-74. doi: 10.1016/j.parkreldis.2013.09.020. Epub 2013 Oct 18.

PMID:
24183677
42.

Mobility, mood and site of care impact health related quality of life in Parkinson's disease.

Nutt JG, Siderowf AD, Guttman M, Schmidt PN, Zamudio JI, Wu SS, Okun MS, Simuni T, Parashos SA, Dahodwala NA, Davis TL, Giladi N, Gurevich T, Hauser RA, Jankovic J, Lyons KE, Marsh L, Miyasaki JM, Morgan JC, Santiago AJ, Tarsy D, Mari Z, Malaty IA, Nelson EC; National Parkinson Foundation Quality Improvement Initiative Investigators.

Parkinsonism Relat Disord. 2014 Mar;20(3):274-9. doi: 10.1016/j.parkreldis.2013.10.004. Epub 2013 Oct 16.

PMID:
24182524
43.

Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.

Mirelman A, Heman T, Yasinovsky K, Thaler A, Gurevich T, Marder K, Bressman S, Bar-Shira A, Orr-Urtreger A, Giladi N, Hausdorff JM; LRRK2 Ashkenazi Jewish Consortium.

Mov Disord. 2013 Oct;28(12):1683-90. doi: 10.1002/mds.25587. Epub 2013 Oct 7.

PMID:
24123150
44.

Falls in Parkinson disease: analysis of a large cross-sectional cohort.

Parashos SA, Wielinski CL, Giladi N, Gurevich T; National Parkinson Foundation Quality Improvement Initiative Investigators.

J Parkinsons Dis. 2013;3(4):515-22. doi: 10.3233/JPD-130249.

PMID:
24113557
45.

Elevated titers of anti-thyroperoxidase antibodies in patients with multiple system atrophy: a pilot study.

Shihman B, Giladi N, Bleiberg M, Rosenberg A, Korczyn AD, Gurevich T.

Clin Neurol Neurosurg. 2013 Nov;115(11):2348-50. doi: 10.1016/j.clineuro.2013.08.013. Epub 2013 Sep 21.

PMID:
24063975
46.

The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease.

Gan-Or Z, Ozelius LJ, Bar-Shira A, Saunders-Pullman R, Mirelman A, Kornreich R, Gana-Weisz M, Raymond D, Rozenkrantz L, Deik A, Gurevich T, Gross SJ, Schreiber-Agus N, Giladi N, Bressman SB, Orr-Urtreger A.

Neurology. 2013 Apr 23;80(17):1606-10. doi: 10.1212/WNL.0b013e31828f180e. Epub 2013 Mar 27.

47.

A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type.

Siri C, Duerr S, Canesi M, Delazer M, Esselink R, Bloem BR, Gurevich T, Balas M, Giladi N, Santacruz P, Marti F, Tolosa E, Rubino A, Meco G, Poewe W, Pezzoli G, Wenning G, Antonini A.

J Neural Transm (Vienna). 2013 Apr;120(4):613-8. doi: 10.1007/s00702-013-0997-x. Epub 2013 Mar 6.

PMID:
23462799
48.

The natural history of multiple system atrophy: a prospective European cohort study.

Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, Köllensperger M, Goebel G, Pfeiffer KP, Barone P, Pellecchia MT, Quinn NP, Koukouni V, Fowler CJ, Schrag A, Mathias CJ, Giladi N, Gurevich T, Dupont E, Ostergaard K, Nilsson CF, Widner H, Oertel W, Eggert KM, Albanese A, del Sorbo F, Tolosa E, Cardozo A, Deuschl G, Hellriegel H, Klockgether T, Dodel R, Sampaio C, Coelho M, Djaldetti R, Melamed E, Gasser T, Kamm C, Meco G, Colosimo C, Rascol O, Meissner WG, Tison F, Poewe W; European Multiple System Atrophy Study Group.

Lancet Neurol. 2013 Mar;12(3):264-74. doi: 10.1016/S1474-4422(12)70327-7. Epub 2013 Feb 5.

49.

White matter hyperintensities in Parkinson's disease: do they explain the disparity between the postural instability gait difficulty and tremor dominant subtypes?

Herman T, Rosenberg-Katz K, Jacob Y, Auriel E, Gurevich T, Giladi N, Hausdorff JM.

PLoS One. 2013;8(1):e55193. doi: 10.1371/journal.pone.0055193. Epub 2013 Jan 31.

50.

Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers.

Thaler A, Mirelman A, Helmich RC, van Nuenen BF, Rosenberg-Katz K, Gurevich T, Orr-Urtreger A, Marder K, Bressman S, Bloem BR, Giladi N, Hendler T; LRRK2 Ashkenazi Jewish consortium.

Cortex. 2013 Oct;49(9):2501-11. doi: 10.1016/j.cortex.2012.12.017. Epub 2013 Jan 7.

PMID:
23357204

Supplemental Content

Loading ...
Support Center